EDIT - Editas Medicine Is Beyond Skepticism Analyst Has Confidence In Sickle Cell Therapy Upgrades Stock | Benzinga
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Analysts Dae Gon Ha and Benazir Ali have upgraded from Hold to Buy with a price target of $17, up from $9.
But with YE23's goal to dose n=20, in addition to important regulatory insights expected from CRISPR Therapeutics AG's (NASDAQ: CRSP) exa-cel, EDIT-301 deserves a fresh look.
Also Read: Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients ...